Achilles Therapeutics Back to portfolio


April 2015
Initial meetings between Syncona and Founders to discuss the merits of the opportunity to develop immunotherapies for cancer.
H2 2015
Syncona begins deep due diligence, partnering with the founders to develop a product format and business plan capable of going all the way to market.
Nov 2015
Syncona achieves Board approval to proceed with Achilles as a portfolio company and begins licencing negotiations.
H1 2016
Syncona begins building a management team to lead Achilles including the appointment of CEO Chris Ashton a CMO and a Head of IP
28 July 2016
Achilles is founded with seed financing of £13.2m from Syncona, to be delivered over a number of tranches.
H2 2016
Syncona continues to provide business development and operational support.
Jan 2017
Achilles establishes a head corporate office and laboratory in Stevenage

Company Details


Immunotherapy for late-stage cancer

Fully diluted ownership


Value of Syncona holding



Achilles’ technology combines recent advances from two of the fastest developing fields in healthcare today, DNA sequencing technology and cancer immunotherapy (“immuno-oncology”), to create a personalised medicine with the potential to cure patients.

Lung cancer accounts for 1.5 million deaths per year globally. In the US alone, more than 200,000 patients are diagnosed with lung cancer every year, for which the 5-year survival rate is less than 20%.


Chris Ashton

Syncona Representatives
  • Iraj Ali
  • Elisa Petris
  • Chris Ashton
  • Prof. Charles Swanton
  • Prof. Karl Peggs
  • Prof. Mark Lowdell
  • Dr. Sergio Quezada